IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0145022.html
   My bibliography  Save this article

Cost-Effectiveness of HBV and HCV Screening Strategies – A Systematic Review of Existing Modelling Techniques

Author

Listed:
  • Claudia Geue
  • Olivia Wu
  • Yiqiao Xin
  • Robert Heggie
  • Sharon Hutchinson
  • Natasha K Martin
  • Elisabeth Fenwick
  • David Goldberg
  • Consortium and ECDC

Abstract

Introduction: Studies evaluating the cost-effectiveness of screening for Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) are generally heterogeneous in terms of risk groups, settings, screening intervention, outcomes and the economic modelling framework. It is therefore difficult to compare cost-effectiveness results between studies. This systematic review aims to summarise and critically assess existing economic models for HBV and HCV in order to identify the main methodological differences in modelling approaches. Methods: A structured search strategy was developed and a systematic review carried out. A critical assessment of the decision-analytic models was carried out according to the guidelines and framework developed for assessment of decision-analytic models in Health Technology Assessment of health care interventions. Results: The overall approach to analysing the cost-effectiveness of screening strategies was found to be broadly consistent for HBV and HCV. However, modelling parameters and related structure differed between models, producing different results. More recent publications performed better against a performance matrix, evaluating model components and methodology. Conclusion: When assessing screening strategies for HBV and HCV infection, the focus should be on more recent studies, which applied the latest treatment regimes, test methods and had better and more complete data on which to base their models. In addition to parameter selection and associated assumptions, careful consideration of dynamic versus static modelling is recommended. Future research may want to focus on these methodological issues. In addition, the ability to evaluate screening strategies for multiple infectious diseases, (HCV and HIV at the same time) might prove important for decision makers.

Suggested Citation

  • Claudia Geue & Olivia Wu & Yiqiao Xin & Robert Heggie & Sharon Hutchinson & Natasha K Martin & Elisabeth Fenwick & David Goldberg & Consortium and ECDC, 2015. "Cost-Effectiveness of HBV and HCV Screening Strategies – A Systematic Review of Existing Modelling Techniques," PLOS ONE, Public Library of Science, vol. 10(12), pages 1-26, December.
    • Handle: RePEc:plo:pone00:0145022
    DOI: 10.1371/journal.pone.0145022
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0145022
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0145022&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0145022?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Carmine Rossi & Kevin Schwartzman & Olivia Oxlade & Marina B Klein & Chris Greenaway, 2013. "Hepatitis B Screening and Vaccination Strategies for Newly Arrived Adult Canadian Immigrants and Refugees: A Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 8(10), pages 1-1, October.
    2. Anouk T Urbanus & Marjolijn van Keep & Amy A Matser & Mark H Rozenbaum & Christine J Weegink & Anneke van den Hoek & Maria Prins & Maarten J Postma, 2013. "Is Adding HCV Screening to the Antenatal National Screening Program in Amsterdam, The Netherlands, Cost-Effective?," PLOS ONE, Public Library of Science, vol. 8(8), pages 1-9, August.
    3. Tormans, G. & Van Damme, P. & Carrin, G. & Clara, R. & Eylenbosch, W., 1993. "Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus--The case of Belgium," Social Science & Medicine, Elsevier, vol. 37(2), pages 173-181, July.
    4. Shan Liu & Lauren E Cipriano & Mark Holodniy & Jeremy D Goldhaber-Fiebert, 2013. "Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States," PLOS ONE, Public Library of Science, vol. 8(3), pages 1-14, March.
    5. Lauren E Cipriano & Gregory S Zaric & Mark Holodniy & Eran Bendavid & Douglas K Owens & Margaret L Brandeau, 2012. "Cost Effectiveness of Screening Strategies for Early Identification of HIV and HCV Infection in Injection Drug Users," PLOS ONE, Public Library of Science, vol. 7(9), pages 1-14, September.
    6. Ruggeri, Matteo & Cicchetti, Americo & Gasbarrini, Antonio, 2011. "The cost-effectiveness of alternative strategies against HBV in Italy," Health Policy, Elsevier, vol. 102(1), pages 72-80, September.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Paul Jülicher & Vladimir P Chulanov & Nikolay N Pimenov & Ekaterina Chirkova & Anna Yankina & Claudio Galli, 2019. "Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis," PLOS ONE, Public Library of Science, vol. 14(7), pages 1-22, July.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Job F. H. Eijsink & Mohamed N. M. T. Al Khayat & Cornelis Boersma & Peter G. J. Horst & Jan C. Wilschut & Maarten J. Postma, 2021. "Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(1), pages 75-88, February.
    2. Olanrewaju Medu & Adegboyega Lawal & Doug Coyle & Kevin Pottie, 2021. "Economic evaluation of HIV testing options for low-prevalence high-income countries: a systematic review," Health Economics Review, Springer, vol. 11(1), pages 1-11, December.
    3. Anita W M Suijkerbuijk & Albert Jan van Hoek & Jelle Koopsen & Robert A de Man & Marie-Josee J Mangen & Hester E de Melker & Johan J Polder & G Ardine de Wit & Irene K Veldhuijzen, 2018. "Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country," PLOS ONE, Public Library of Science, vol. 13(11), pages 1-16, November.
    4. Giovanni S. P. Malloy & Jeremy D. Goldhaber-Fiebert & Eva A. Enns & Margaret L. Brandeau, 2021. "Predicting the Effectiveness of Endemic Infectious Disease Control Interventions: The Impact of Mass Action versus Network Model Structure," Medical Decision Making, , vol. 41(6), pages 623-640, August.
    5. Ting-Yu Ho & Shan Liu & Zelda B. Zabinsky, 2019. "A Multi-Fidelity Rollout Algorithm for Dynamic Resource Allocation in Population Disease Management," Health Care Management Science, Springer, vol. 22(4), pages 727-755, December.
    6. Hani Serag & Isabel Clark & Cherith Naig & David Lakey & Yordanos M. Tiruneh, 2022. "Financing Benefits and Barriers to Routine HIV Screening in Clinical Settings in the United States: A Scoping Review," IJERPH, MDPI, vol. 20(1), pages 1-13, December.
    7. Roy Lothan & Noa Gutman & Dan Yamin, 2022. "Country versus pharmaceutical company interests for hepatitis C treatment," Health Care Management Science, Springer, vol. 25(4), pages 725-749, December.
    8. Bassem Asker & Raghad Jawad & Rabah Asreah & Haydar Jamal & Ahmed Jassem & Muslim Abdelkareem Inaya & Hiwa Abou Baker & Sam Kozma & Eid Mansour & Bryony McNamara & Ryan Miller & Oliver Darlington & Ph, 2021. "Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment," PharmacoEconomics, Springer, vol. 39(11), pages 1327-1341, November.
    9. Shan Liu & Margaret L. Brandeau & Jeremy D. Goldhaber-Fiebert, 2017. "Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment," Health Care Management Science, Springer, vol. 20(1), pages 16-32, March.
    10. Lauren E. Cipriano & Thomas A. Weber, 2018. "Population-level intervention and information collection in dynamic healthcare policy," Health Care Management Science, Springer, vol. 21(4), pages 604-631, December.
    11. Lauren E. Cipriano & Shan Liu & Kaspar S. Shahzada & Mark Holodniy & Jeremy D. Goldhaber-Fiebert, 2018. "Economically Efficient Hepatitis C Virus Treatment Prioritization Improves Health Outcomes," Medical Decision Making, , vol. 38(7), pages 849-865, October.
    12. Daniel T Myran & Rachael Morton & Beverly-Ann Biggs & Irene Veldhuijzen & Francesco Castelli & Anh Tran & Lukas P Staub & Eric Agbata & Prinon Rahman & Manish Pareek & Teymur Noori & Kevin Pottie, 2018. "The Effectiveness and Cost-Effectiveness of Screening for and Vaccination Against Hepatitis B Virus among Migrants in the EU/EEA: A Systematic Review," IJERPH, MDPI, vol. 15(9), pages 1-19, September.
    13. Bert, Fabrizio & Gualano, Maria Rosaria & Biancone, Paolo & Brescia, Valerio & Camussi, Elisa & Martorana, Maria & Secinaro, Silvana & Siliquini, Roberta, 2018. "Cost-effectiveness of HIV screening in high-income countries: A systematic review," Health Policy, Elsevier, vol. 122(5), pages 533-547.
    14. Carla Osiowy & Elizabeth Giles & Max Trubnikov & Yogesh Choudhri & Anton Andonov, 2015. "Characterization of Acute and Chronic Hepatitis B Virus Genotypes in Canada," PLOS ONE, Public Library of Science, vol. 10(9), pages 1-20, September.
    15. Eva A. Enns & Lauren E. Cipriano & Cyrena T. Simons & Chung Yin Kong, 2015. "Identifying Best-Fitting Inputs in Health-Economic Model Calibration," Medical Decision Making, , vol. 35(2), pages 170-182, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0145022. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.